The new coronavirus (SARS CoV 2) as a cause of dizziness or hearing loss in the COVID 19 pandemic

Marcello Cherchi, MD, PhD. Return to Index. • Page last modified: April 3, 2021

The pandemic of the coronavirus disease that began in 2019 (COVID 19) has posed a number of challenges for patients and for physicians. Its repercussions are changing rapidly, and our understanding of the disease itself is evolving.

How COVID 19 attacks the body

The pathogen (technically called “severe acute respiratory syndrome coronavirus type 2” or “SARS CoV 2”) belongs to a family of coronaviruses, which are single-stranded RNA viruses contained in a lipid bilayer envelope from which there protrude spike glycoproteins that comprise the “hooks” that let the viruses gain entry into host cells, where they replicate and propagate. These “hooks” attach particularly well to angiotensin-converting enzyme receptors (Ceccarelli, Berretta M Fau - Venanzi Rullo et al. 2020, Yan, Zhang et al. 2020) that are densely expressed in cells in the lungs, which is thought to be why some of the initial and most prominent symptoms of infection involve the respiratory tract, though unfortunately, the disease is not limited to the respiratory tract.

How COVID 19 attacks the brain:

The mechanism by which coronaviruses enter the central nervous system (CNS), and the factors that make specific people vulnerable to this, are incompletely understood (Dales 1995, Dube, Le Coupanec et al. 2018), though recent evidence (Baig, Khaleeq et al. 2020) has demonstrated that there are cells within the CNS that express angiotensin converting enzyme receptors — albeit at a lower density than in the lower respiratory tract. In any case, once the viruses have gained entry into the CNS, they appear capable of advancing by axonal transport (Dube, Le Coupanec et al. 2018).

Other members of the coronavirus family have long been known to invade the central nervous system, and have been found the brain/spinal cord tissue or the cerebrospinal fluid of patients suffering from a variety of neurological diseases, prominent among which are multiple sclerosis (Burks, DeVald et al. 1980, Salmi, Ziola et al. 1982, Hovanec and Flanagan 1983), Parkinson's disease (Fazzini, Fleming et al. 1992), optic neuritis (Dessau, Lisby et al. 1999), encephalitis (Arabi, Harthi et al. 2015, Li, Li et al. 2016, Morfopoulou, Brown et al. 2016, Nilsson, Edner et al. 2020) and acute disseminated encephalomyelitis (Yeh, Collins et al. 2004). In some of these diseases (e.g., optic neuritis, encephalitis and encephalomyelitis) it is reasonable to suspect that the virus itself is the cause of the disease, while in other conditions (e.g., multiple sclerosis, Parkinson's disease) it is unclear whether the virus has any causative role.

Early in the pandemic it was noted that patients infected with COVID 19 could exhibit neurologic symptoms (Koralnik and Tyler 2020, Pinzon, Wijaya et al. 2020), particularly when the illness was severe enough to warrant hospitalization (Liotta, Batra et al. 2020) and management in an intensive care unit (Pinna, Grewal et al. 2020). The accumulating evidence (Filatov, Sharma et al. 2020, Nath 2020, Poyiadji, Shahin et al. 2020) specifically about the virus causing COVID 19 suggests that it can affect the CNS similarly to other members of coronavirus family (Zubair, McAlpine et al. 2020), though there are differences as well (Ceccarelli, Berretta M Fau - Venanzi Rullo et al. 2020), such as its apparent predilection to impair smell and taste (Gautier and Ravussin 2020, Giacomelli, Pezzati et al. 2020, Mao, Jin et al. 2020, Mermelstein 2020, Vavougios 2020). It is thus reasonable to consider whether it might also be the mechanism for other focal neurological manifestations, including the auditory and vertiginous disorders that we see in clinic — though to be clear, this disease is so new that there has not yet been adequate opportunity to study this in any systematic fashion. Emerging clinical literature (Saniasiaya and Kulasegarah 2021) describes dizziness as a symptom associated with COVID 19, which matches our own clinical experience; a few months into the pandemic we began encountering patients with a laboratory-confirmed diagnosis of COVID 19 who complained of dizziness.

COVID 19 as the cause of hearing disorders and vertigo/imbalance

One case series from the United Kingdom noted that >10% of COVID 19 confirmed patients self-reported auditory symptoms of hearing loss and/or tinnitus (Munro, Uus et al. 2020). A large case series (799 patients) from Wuhan described dizziness as a symptom in 8% of confirmed COVID 19 patients (Chen, Wu et al. 2020), though another study (214 patients) from Wuhan specifically querying neurological symptoms among confirmed cases of COVID 19 reported dizziness in 16.8% of patients (Mao, Jin et al. 2020); a study from a network of Chicago area hospitals (509 patients) reported dizziness in 29.7% of cases (Liotta, Batra et al. 2020). Reviews of the emerging literature note this variability among studies (Saniasiaya and Kulasegarah 2021). The ability of COVID 19 to cause auditory and vestibular symptoms appears to be distinct from the other SARS coronaviruses (Almufarrij, Uus et al. 2020). The mechanism by which COVID 19 may cause hearing loss, tinnitus and dizziness is unclear; since the disease appears to be capable of affecting individual cranial nerves — as happens in anosmia (Gautier and Ravussin 2020, Giacomelli, Pezzati et al. 2020, Mao, Jin et al. 2020, Mermelstein 2020, Vavougios 2020), optic neuritis (Dessau, Lisby et al. 1999) and ophthalmoparesis (Dinkin, Gao et al. 2020) — it is conceivable that it causes vestibular neuritis and/or cochlear neuritis, though this remains a conjecture requiring further study.

Vaccines for COVID 19

As of this writing several vaccines have received emergency-basis permission from the FDA for use (Polack, Thomas et al. 2020, Baden, El Sahly et al. 2021). We have received questions from patients regarding whether the vaccines themselves can cause dizziness, and whether the vaccines can exacerbate a pre existing "dizzy disease." There are still insufficient data to answer these questions. Our experience so far has been that (1) apparent adverse effects from the vaccines have been transient, lasting up to several days; (2) although symptoms from COVID 19 infection itself can be very mild, they can also be devastating (if a patient survives) or lethal. On the whole, the potential protection conferred by receiving the vaccines appears greatly to outweigh the risk of the vaccines.


Almufarrij, I., K. Uus and K. J. Munro (2020). "Does coronavirus affect the audio-vestibular system? A rapid systematic review." Int J Audiol 59(7): 487-491.
Arabi, Y. M., A. Harthi, J. Hussein, A. Bouchama, S. Johani, A. H. Hajeer, B. T. Saeed, A. Wahbi, A. Saedy, T. AlDabbagh, R. Okaili, M. Sadat and H. Balkhy (2015). "Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)." Infection 43(4): 495-501.
Baden, L. R., H. M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S. A. Spector, N. Rouphael, C. B. Creech, J. McGettigan, S. Khetan, N. Segall, J. Solis, A. Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich, J. Mascola, L. Polakowski, J. Ledgerwood, B. S. Graham, H. Bennett, R. Pajon, C. Knightly, B. Leav, W. Deng, H. Zhou, S. Han, M. Ivarsson, J. Miller, T. Zaks and C. S. Group (2021). "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine." N Engl J Med 384(5): 403-416.
Baig, A. M., A. Khaleeq, U. Ali and H. Syeda (2020). "Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms." ACS Chem Neurosci 11(7): 995-998.
Burks, J. S., B. L. DeVald, L. D. Jankovsky and J. C. Gerdes (1980). "Two coronaviruses isolated from central nervous system tissue of two multiple sclerosis patients." Science 209(4459): 933-934.
Ceccarelli, M., E. Berretta M Fau - Venanzi Rullo, G. Venanzi Rullo E Fau - Nunnari, B. Nunnari G Fau - Cacopardo and B. Cacopardo (2020). "Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet?" European Review for Medical and Pharmacological Sciences 24(2284-0729 (Electronic)).
Chen, T., D. Wu, H. Chen, W. Yan, D. Yang, G. Chen, K. Ma, D. Xu, H. Yu, H. Wang, T. Wang, W. Guo, J. Chen, C. Ding, X. Zhang, J. Huang, M. Han, S. Li, X. Luo, J. Zhao and Q. Ning (2020). "Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study." BMJ 368: m1091.
Dales, S. (1995). "Factors controlling coronavirus infections and disease of the central nervous system. A review." Adv Exp Med Biol 380: 13-22.
Dessau, R. B., G. Lisby and J. L. Frederiksen (1999). "Coronaviruses in spinal fluid of patients with acute monosymptomatic optic neuritis." Acta Neurol Scand 100(2): 88-91.
Dinkin, M., V. Gao, J. Kahan, S. Bobker, M. Simonetto, P. Wechsler, J. Harpe, C. Greer, G. Mints, G. Salama, A. J. Tsiouris and D. Leifer (2020). "COVID-19 presenting with ophthalmoparesis from cranial nerve palsy." Neurology.
Dube, M., A. Le Coupanec, A. H. M. Wong, J. M. Rini, M. Desforges and P. J. Talbot (2018). "Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43." J Virol 92(17).
Fazzini, E., J. Fleming and S. Fahn (1992). "Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease." Mov Disord 7(2): 153-158.
Filatov, A., P. Sharma, F. Hindi and P. S. Espinosa (2020). "Neurological complications of coronavirus disease (COVID-19): Encephalopathy." Cureus 12(3): e7352.
Gautier, J. F. and Y. Ravussin (2020). "A New Symptom of COVID-19: Loss of Taste and Smell." Obesity (Silver Spring).
Giacomelli, A., L. Pezzati, F. Conti, D. Bernacchia, M. Siano, L. Oreni, S. Rusconi, C. Gervasoni, A. L. Ridolfo, G. Rizzardini, S. Antinori and M. Galli (2020). "Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study." Clin Infect Dis.
Hovanec, D. L. and T. D. Flanagan (1983). "Detection of antibodies to human coronaviruses 229E and OC43 in the sera of multiple sclerosis patients and normal subjects." Infect Immun 41(1): 426-429.
Koralnik, I. J. and K. L. Tyler (2020). "COVID-19: A Global Threat to the Nervous System." Ann Neurol 88(1): 1-11.
Li, Y., H. Li, R. Fan, B. Wen, J. Zhang, X. Cao, C. Wang, Z. Song, S. Li, X. Li, X. Lv, X. Qu, R. Huang and W. Liu (2016). "Coronavirus Infections in the Central Nervous System and Respiratory Tract Show Distinct Features in Hospitalized Children." Intervirology 59(3): 163-169.
Liotta, E. M., A. Batra, J. R. Clark, N. A. Shlobin, S. C. Hoffman, Z. S. Orban and I. J. Koralnik (2020). "Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients." Ann Clin Transl Neurol.
Mao, L., H. Jin, M. Wang, Y. Hu, S. Chen, Q. He, J. Chang, C. Hong, Y. Zhou, D. Wang, X. Miao, Y. Li and B. Hu (2020). "Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China." JAMA Neurol.
Mermelstein, S. (2020). "Acute anosmia from COVID-19 infection." Pract Neurol.
Morfopoulou, S., J. R. Brown, E. G. Davies, G. Anderson, A. Virasami, W. Qasim, W. K. Chong, M. Hubank, V. Plagnol, M. Desforges, T. S. Jacques, P. J. Talbot and J. Breuer (2016). "Human Coronavirus OC43 Associated with Fatal Encephalitis." N Engl J Med 375(5): 497-498.
Munro, K. J., K. Uus, I. Almufarrij, N. Chaudhuri and V. Yioe (2020). "Persistent self-reported changes in hearing and tinnitus in post-hospitalisation COVID-19 cases." Int J Audiol: 1-2.
Nath, A. (2020). "Neurologic complications of coronavirus infections." Neurology.
Nilsson, A., N. Edner, J. Albert and A. Ternhag (2020). "Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child." Infect Dis (Lond): 1-4.
Pinna, P., P. Grewal, J. P. Hall, T. Tavarez, R. M. Dafer, R. Garg, N. D. Osteraas, D. R. Pellack, A. Asthana, K. Fegan, V. Patel, J. J. Conners, S. John and I. D. Silva (2020). "Neurological manifestations and COVID-19: Experiences from a tertiary care center at the Frontline." J Neurol Sci 415: 116969.
Pinzon, R. T., V. O. Wijaya, R. B. Buana, A. Al Jody and P. N. Nunsio (2020). "Neurologic Characteristics in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis." Front Neurol 11: 565.
Polack, F. P., S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez, G. Perez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S. Roychoudhury, K. Koury, P. Li, W. V. Kalina, D. Cooper, R. W. Frenck, Jr., L. L. Hammitt, O. Tureci, H. Nell, A. Schaefer, S. Unal, D. B. Tresnan, S. Mather, P. R. Dormitzer, U. Sahin, K. U. Jansen, W. C. Gruber and C. C. T. Group (2020). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine." N Engl J Med 383(27): 2603-2615.
Poyiadji, N., G. Shahin, D. Noujaim, M. Stone, S. Patel and B. Griffith (2020). "COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features." Radiology: 201187.
Salmi, A., B. Ziola, T. Hovi and M. Reunanen (1982). "Antibodies to coronaviruses OC43 and 229E in multiple sclerosis patients." Neurology 32(3): 292-295.
Saniasiaya, J. and J. Kulasegarah (2021). "Dizziness and COVID-19." Ear Nose Throat J 100(1): 29-30.
Vavougios, G. D. (2020). "Potentially irreversible olfactory and gustatory impairments in COVID-19: Indolent vs. fulminant SARS-CoV-2 neuroinfection." Brain Behav Immun.
Yan, R., Y. Zhang, Y. Li, L. Xia, Y. Guo and Q. Zhou (2020). "Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2." Science 367(6485): 1444-1448.
Yeh, E. A., A. Collins, M. E. Cohen, P. K. Duffner and H. Faden (2004). "Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis." Pediatrics 113(1 Pt 1): e73-76.
Zubair, A. S., L. S. McAlpine, T. Gardin, S. Farhadian, D. E. Kuruvilla and S. Spudich (2020). "Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review." JAMA Neurol 77(8): 1018-1027.